Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient...

Ogkologos - 31 Μαΐου, 2024

World No Tobacco Day 2024: European Societies call for an EU...

Ogkologos - 30 Μαΐου, 2024

Tovorafenib Approved for Some Children with Low-Grade Glioma

Ogkologos - 28 Μαΐου, 2024

Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced...

Ogkologos - 28 Μαΐου, 2024

Adding 24 Months of ADT Improves Metastasis-Free Survival in Patients with...

Ogkologos - 27 Μαΐου, 2024

FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell...

Ogkologos - 24 Μαΐου, 2024

Neoadjuvant Dabrafenib Plus Trametinib Has High Pathological Response Rates in Clinical...

Ogkologos - 24 Μαΐου, 2024

EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of...

Ogkologos - 23 Μαΐου, 2024

Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than...

Ogkologos - 22 Μαΐου, 2024

Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer

Ogkologos - 21 Μαΐου, 2024

1...818283...440 Σελίδα 82 από 440

MOST POPULAR

EMA Recommends Granting a Marketing Authorisation for Fruquintinib

13 Μαΐου, 2024

A peek behind the scenes: Just how are our funding decisions...

6 Ιουλίου, 2022

Niraparib Maintenance Significantly Reduces the Risk of Disease Progression or Death...

31 Ιουλίου, 2023

Cancer and the Holidays

3 Δεκεμβρίου, 2021

Φόρτωση περισσοτέρων

Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient...

World No Tobacco Day 2024: European Societies call for an EU...

Tovorafenib Approved for Some Children with Low-Grade Glioma

Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced...

Adding 24 Months of ADT Improves Metastasis-Free Survival in Patients with...

FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell...

Neoadjuvant Dabrafenib Plus Trametinib Has High Pathological Response Rates in Clinical...

EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of...

Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than...

Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer

MOST POPULAR

EMA Recommends Granting a Marketing Authorisation for Fruquintinib

A peek behind the scenes: Just how are our funding decisions...

Niraparib Maintenance Significantly Reduces the Risk of Disease Progression or Death...

Cancer and the Holidays

HOT NEWS

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

Program Helps Medically Underserved, Minority Cancer Survivors Be More Active

Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite...

Foodie Fridays-Gazpacho: A Favorite Summer Soup

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ